Okay, so I need to figure out why terlipressin is preferred over vasopressin for esophageal varices. Let me start by recalling what I know about these drugs. Both are vasopressors, right? Vasopressin acts on V1 receptors to cause vasoconstriction, which can reduce portal hypertension. But I remember that vasopressin can cause severe side effects, especially coronary vasoconstriction, which is dangerous in patients with heart issues.

Terlipressin is a longer-acting analog of vasopressin. Maybe it's more selective or has a different receptor profile? Wait, terlipressin has more activity at V1A receptors and less at V2, which are in the kidneys. But why would that matter for esophageal varices? Oh, right, the main issue with vasopressin is its systemic vasoconstriction leading to ischemia in various organs, like the coronary arteries and mesenteric vessels. Terlipressin might have a better balance, causing less vasoconstriction in those critical areas while still reducing portal pressure.

So the question is about why terlipressin is preferred. The options aren't given, but common reasons I've studied include terlipressin having a longer duration of action, fewer systemic side effects, or better efficacy. Let me think about the pharmacokinetics. Terlipressin is a tetrapeptide with a longer half-life, so it can be given less frequently. Also, it's less likely to cause tachycardia or coronary vasoconstriction compared to vasopressin.

Another angle: vasopressin can cause tachycardia as a side effect, while terlipressin might not. Or maybe terlipressin has more V1A selectivity, leading to better portal pressure reduction without the systemic vasoconstriction. The key point is that in variceal bleeding, you want to reduce portal pressure but avoid ischemia in other organs. Terlipressin's profile makes it safer for this purpose.

Wait, but some sources mention that terlipressin is more potent in reducing portal pressure. However, the main advantage is probably the adverse effect profile. Vasopressin can cause myocardial ischemia, especially in patients with coronary artery disease. Terlipressin's lower affinity for coronary V1 receptors might reduce this risk, making it the preferred choice. So the correct answer would be about fewer adverse effects, particularly in the coronary arteries, leading to better patient outcomes when managing esophageal varices.

**Core Concept**
Terlipressin is a long-acting vasopressin analog preferred for acute variceal bleeding due to its superior hemodynamic profile. It selectively reduces portal pressure while minimizing systemic vasoconstriction, particularly in coronary and mesenteric vessels. This is critical in preventing ischemia during treatment.

**Why the Correct Answer is Right**
Terlipressin acts primarily on V1A receptors in splanchnic vessels to decrease portal venous pressure. Its structure (tetrapeptide with two disulfide bonds) prolongs half-life and reduces affinity for coronary V1 receptors compared to vasopressin. This minimizes coronary vasoconstriction and tachycardia, making it safer for patients with cardiovascular comorbidities. It also avoids the rapid, severe systemic

✓ Correct Answer: C. Less side effects